Treatments
Source: OpenFDA drug label API · last checked
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
From the FDA label: 1 INDICATIONS AND USAGE COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic med…
Kinase Inhibitor [EPC] · Rearranged during Transfection (RET) Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). (…
From the FDA label: 1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FD…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
l-Thyroxine [EPC] · l-Triiodothyronine [EPC]
From the FDA label: INDICATIONS AND USAGE RenThyroid (Thyroid Tablets, USP) are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis…
From the FDA label: 1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) conge…
l-Thyroxine [EPC] · l-Triiodothyronine [EPC]
From the FDA label: INDICATIONS AND USAGE: NP Thyroid® tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacut…
From the FDA label: 1 INDICATIONS AND USAGE Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidis…
From the FDA label: INDICATIONS AND USAGE Armour Thyroid (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyr…
From the FDA label: INDICATIONS AND USAGE Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This cat…
Trials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Thyroid Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.